FORM 4

to Section 16. Form 4 or Form 5 obligations may continue. See

Instruction 1(b).

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

wasnington,	D.C. 20549

Check this box if no longer subject to Section 16 Form 4 or Form 5

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name ar	2. Issuer Name and Ticker or Trading Symbol Black Diamond Therapeutics, Inc. [ BDTX ]										all app Direc	,	ng Per	10% O	wner					
(Last)	(Last) (First) (Middle) C/O BLACK DIAMOND THERAPEUTICS, INC.							3. Date of Earliest Transaction (Month/Day/Year) 06/17/2022										Other ( below)	specify	
ONE MAIN STREET, 14TH FLOOR															vidual a	r Joint/Crow	n Filine	a (Chook A	nnliaghla	-
(Street) CAMBRIDGE MA 02142						4. If Amendment, Date of Original Filed (Month/Day/Year) 06/17/2022									6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(St	ate) (Z	Zip)																	
		Table	I - No	n-Deriva	tive S	Secu	rities	Acq	uired,	Dis	posed of	, or B	Benefi	icially	Own	ed				
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day						Execution					es Acquired (A Of (D) (Instr. 3,			Securi Benefi Owned	. Amount of securities seneficially owned Following seported		vnership n: Direct r Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) or (D)		ice	Transaction(s) (Instr. 3 and 4)				(111041.4)	
Common Stock 06/17/2						2022					4,946	A	\$2	2.03(2)	4,946			D		
		Tal	ble II -								osed of, convertib				Owne	d				
1. Title of Derivative Security (Instr. 3)	ivative Conversion Date Execution Date, urity or Exercise (Month/Day/Year) if any		ion Date,	4. Transaction Code (Instr. 8)		of Deriv Secu Acqu (A) o Dispo of (D (Instr			6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		Price of rivative curity str. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	t I	
			Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	or Number of Shares									

## **Explanation of Responses:**

- 1. These shares were issued in accordance with the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.
- 2. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 16, 2022.

## Remarks:

On June 17, 2022 the Reporting Person filed a Form 4 (the "Original Form 4"), which inadvertently understated the number of shares of Common Stock issued to the Reporting Person by 886 shares. This amendment is being filed to correct the amounts listed in Columns 4 and 5 of Table I, and there have been no other changes to the information presented in the Original Form 4.

/s/ Brent Hatzis-Schoch, Attorney-in-Fact 06/30/2022

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.